Entyvio 300 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FBPZQ
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $49,663
Award facts
- Contract value 100% obligated
- $49,662.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $49,662.50 by the Defense Logistics Agency on January 5, 2026, for the supply of Entyvio 300 mg vials. The award carries an ultimate completion date of January 6, 2026, and was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR, which was established on November 13, 2025, with a $499.999 billion ceiling value extending through December 31, 2036.
The PPV-G GEN V program represents a $30.3 billion acquisition strategy under which the Defense Logistics Agency authorizes multiple regional prime vendor contractors to supply pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to support the recurring medical supply needs of Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group's established performance on numerous prior delivery orders for specialty pharmaceuticals, immunosuppressants, biologics, vaccines, and routine medications demonstrates its capability to fulfill the diverse pharmaceutical requirements of the federal military medical system through this critical supply contract.
Quick answers
Who was awarded contract SPE2DR26FBPZQ?
SPE2DR26FBPZQ was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 5, 2026.
How much is contract SPE2DR26FBPZQ worth?
The government has obligated $49,663 on SPE2DR26FBPZQ.
Is contract SPE2DR26FBPZQ an order under another contract?
Yes. SPE2DR26FBPZQ is a delivery order under SPE2DR25D9304, an indefinite delivery contract.
Was contract SPE2DR26FBPZQ competed?
The extent of competition for SPE2DR26FBPZQ was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award